Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
AKBA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.80 - $2.89
Previous CloseN/A
Volume5.66M
Average Volume (3M)4.21M
Market Cap
$532.91M
Enterprise Value$434.77M
Total Cash (Recent Filing)$51.87M
Total Debt (Recent Filing)$47.64M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
May 12, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding261,231,050
10 Day Avg. Volume8,503,931
30 Day Avg. Volume4,207,615
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.14
Price to Cash Flow (P/CF)-28.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda-31.69
Forecast
1Y Price Target
$7.83Price Target Upside283.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Akebia Therapeutics News
PremiumCompany Announcements
Akebia Therapeutics Announces Public Offering Pricing---
Bulls Say, Bears Say
Bulls Say
Commercial StrategyEarly commercial traction for Vafseo has been strong with an accelerating pace of scripts written.
Market CoverageVafseo launched with nearly 100% contract coverage as the only HIF stabilizer, only oral Tx option, and only non-ESA Tx option available in the US to treat CKD anemia.
Regulatory ApprovalCMS has granted TDAPA designation for Vafseo, making it eligible to receive additional reimbursement on top of the ESRD bundled rate for two years starting 1/1/2025.
Bears Say
Financial RiskThe inability to raise sufficient capital at reasonable terms is considered a risk to the investment thesis and target price.
Market Size And CompetitionRisks to the investment thesis and target price include a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing for Vafseo.
Regulatory ChallengesAdditional regulatory requirements could represent significant timeline delays.
---
Ownership Overview
11.62% Insiders
7.48% Mutual Funds
3.94% Other Institutional Investors
67.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $0.80 and its highest was $2.89 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Akebia Therapeutics’s market cap is $532.91M.
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 48 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Mar 13, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.081 by -$0.019.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -0.05.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 261,231,050 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.081. Following the earnings report the stock price went down -12.435%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Among the largest hedge funds holding Akebia Therapeutics’s share is Graham Capital Management, L.P.. It holds Akebia Therapeutics’s shares valued at 0.
---
Akebia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.83 (283.82% Upside)
$7.83 (283.82% Upside)
Blogger Sentiment
Neutral
AKBA Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 57.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.99%
12-Months-Change
Fundamentals
Return on Equity
91.25%
Trailing 12-Months
Asset Growth
-8.70%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
---
AKBA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights a strong initial launch of Vafseo with higher-than-expected revenue and broad market access. There is positive momentum in Medicare Advantage uptake and a solid financial position with sufficient cash runway. However, challenges include decreased Auryxia revenue, specialty pharmacy fulfillment issues, and increased net loss. Overall, the sentiment remains cautiously optimistic due to the strong Vafseo launch and regulatory progress.Read More>---
AKBA Stock 12 Month Forecast
Average Price Target
$7.83
▲(283.82% Upside)
Technical Analysis
Best Analysts Covering AKBA
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+15.49%
reiterated a buy rating 9 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +15.49% per trade.
---